APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Cell Therapy CDMO

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Gene Cell Therapy CDMO Industry Growth and Trends Forecast to 2032

4 January 2026113 pages

Choose your research edition.

Industry ResearchGene Cell Therapy CDMO Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Cell Therapy CDMO Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Gene Cell Therapy CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Cell Therapy CDMO Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Cell Therapy CDMO Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

According to APO Research, the global Gene Cell Therapy CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Gene Cell Therapy CDMO market include Catalent, Lonza, Charles River, Oxford Biomedica, Novartis, OBiO, GenScript, Pharmaron and Porton, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Gene Cell Therapy CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Gene Cell Therapy CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Gene Cell Therapy CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Gene Cell Therapy CDMO.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Gene Cell Therapy CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Gene Cell Therapy CDMO Market by Company

Catalent

Lonza

Charles River

Oxford Biomedica

Novartis

OBiO

GenScript

Pharmaron

Porton

Resilience

SK Pharmteco

Forge Biologics

Andelyn Biosciences

Roslin CT

eXmoor Pharma

Advanced Therapies

Catalent Biologics

Patheon Pharma Services

Gene Cell Therapy CDMO Segment by Type

Immune Cells

Stem Cell

Viral Vector

Plasmid DNA

Gene Cell Therapy CDMO Segment by Application

Pharmaceutical and Biotechnology Companies

Research and Academic Institutions

Hospital

Others

Gene Cell Therapy CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Cell Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Cell Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Cell Therapy CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Gene Cell Therapy CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Gene Cell Therapy CDMO Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Gene Cell Therapy CDMO Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Gene Cell Therapy CDMO Market Share by Region (2021-2026) Table 4. Global Gene Cell Therapy CDMO Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Gene Cell Therapy CDMO Market Share by Region (2027-2032) Table 6. Global Gene Cell Therapy CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Gene Cell Therapy CDMO Market Size Share by Type (2021-2026) Table 9. Global Gene Cell Therapy CDMO Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Gene Cell Therapy CDMO Market Size Share Forecasted by Type (2027-2032) Table 11. North America Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Gene Cell Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Gene Cell Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Gene Cell Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Gene Cell Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Gene Cell Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Gene Cell Therapy CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Gene Cell Therapy CDMO Market Size Share by Application (2021-2026) Table 24. Global Gene Cell Therapy CDMO Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Gene Cell Therapy CDMO Market Size Share Forecasted by Application (2027-2032) Table 26. North America Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Gene Cell Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Gene Cell Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Gene Cell Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Gene Cell Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Gene Cell Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Gene Cell Therapy CDMO Industry Trends Table 37. Gene Cell Therapy CDMO Industry Drivers Table 38. Gene Cell Therapy CDMO Industry Opportunities and Challenges Table 39. Gene Cell Therapy CDMO Industry Restraints Table 40. Global Gene Cell Therapy CDMO Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Gene Cell Therapy CDMO Revenue Market Share by Company (2021-2026) Table 42. Global Gene Cell Therapy CDMO Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Gene Cell Therapy CDMO Key Company Headquarters & Area Served Table 44. Global Gene Cell Therapy CDMO Company, Product Type & Application Table 45. Global Gene Cell Therapy CDMO Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Gene Cell Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Catalent Company Information Table 49. Catalent Business Overview Table 50. Catalent Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Catalent Gene Cell Therapy CDMO Product Portfolio Table 52. Catalent Recent Development Table 53. Lonza Company Information Table 54. Lonza Business Overview Table 55. Lonza Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Lonza Gene Cell Therapy CDMO Product Portfolio Table 57. Lonza Recent Development Table 58. Charles River Company Information Table 59. Charles River Business Overview Table 60. Charles River Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Charles River Gene Cell Therapy CDMO Product Portfolio Table 62. Charles River Recent Development Table 63. Oxford Biomedica Company Information Table 64. Oxford Biomedica Business Overview Table 65. Oxford Biomedica Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Oxford Biomedica Gene Cell Therapy CDMO Product Portfolio Table 67. Oxford Biomedica Recent Development Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Novartis Gene Cell Therapy CDMO Product Portfolio Table 72. Novartis Recent Development Table 73. OBiO Company Information Table 74. OBiO Business Overview Table 75. OBiO Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. OBiO Gene Cell Therapy CDMO Product Portfolio Table 77. OBiO Recent Development Table 78. GenScript Company Information Table 79. GenScript Business Overview Table 80. GenScript Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. GenScript Gene Cell Therapy CDMO Product Portfolio Table 82. GenScript Recent Development Table 83. Pharmaron Company Information Table 84. Pharmaron Business Overview Table 85. Pharmaron Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Pharmaron Gene Cell Therapy CDMO Product Portfolio Table 87. Pharmaron Recent Development Table 88. Porton Company Information Table 89. Porton Business Overview Table 90. Porton Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Porton Gene Cell Therapy CDMO Product Portfolio Table 92. Porton Recent Development Table 93. Resilience Company Information Table 94. Resilience Business Overview Table 95. Resilience Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Resilience Gene Cell Therapy CDMO Product Portfolio Table 97. Resilience Recent Development Table 98. SK Pharmteco Company Information Table 99. SK Pharmteco Business Overview Table 100. SK Pharmteco Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. SK Pharmteco Gene Cell Therapy CDMO Product Portfolio Table 102. SK Pharmteco Recent Development Table 103. Forge Biologics Company Information Table 104. Forge Biologics Business Overview Table 105. Forge Biologics Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Forge Biologics Gene Cell Therapy CDMO Product Portfolio Table 107. Forge Biologics Recent Development Table 108. Andelyn Biosciences Company Information Table 109. Andelyn Biosciences Business Overview Table 110. Andelyn Biosciences Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Andelyn Biosciences Gene Cell Therapy CDMO Product Portfolio Table 112. Andelyn Biosciences Recent Development Table 113. Roslin CT Company Information Table 114. Roslin CT Business Overview Table 115. Roslin CT Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Roslin CT Gene Cell Therapy CDMO Product Portfolio Table 117. Roslin CT Recent Development Table 118. eXmoor Pharma Company Information Table 119. eXmoor Pharma Business Overview Table 120. eXmoor Pharma Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. eXmoor Pharma Gene Cell Therapy CDMO Product Portfolio Table 122. eXmoor Pharma Recent Development Table 123. Advanced Therapies Company Information Table 124. Advanced Therapies Business Overview Table 125. Advanced Therapies Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Advanced Therapies Gene Cell Therapy CDMO Product Portfolio Table 127. Advanced Therapies Recent Development Table 128. Catalent Biologics Company Information Table 129. Catalent Biologics Business Overview Table 130. Catalent Biologics Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Catalent Biologics Gene Cell Therapy CDMO Product Portfolio Table 132. Catalent Biologics Recent Development Table 133. Patheon Pharma Services Company Information Table 134. Patheon Pharma Services Business Overview Table 135. Patheon Pharma Services Gene Cell Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Patheon Pharma Services Gene Cell Therapy CDMO Product Portfolio Table 137. Patheon Pharma Services Recent Development Table 138. North America Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Gene Cell Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Gene Cell Therapy CDMO Market Share by Country (2021-2026) Table 141. North America Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Gene Cell Therapy CDMO Market Share Forecast by Country (2027-2032) Table 143. Europe Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe Gene Cell Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe Gene Cell Therapy CDMO Market Share by Country (2021-2026) Table 146. Europe Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe Gene Cell Therapy CDMO Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Gene Cell Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Gene Cell Therapy CDMO Market Share by Country (2021-2026) Table 151. Asia-Pacific Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Gene Cell Therapy CDMO Market Share Forecast by Country (2027-2032) Table 153. Latin America Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America Gene Cell Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America Gene Cell Therapy CDMO Market Share by Country (2021-2026) Table 156. Latin America Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America Gene Cell Therapy CDMO Market Share Forecast by Country (2027-2032) Table 158. Middle East & Africa Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East & Africa Gene Cell Therapy CDMO Market Share by Country (2021-2026) Table 161. Middle East & Africa Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East & Africa Gene Cell Therapy CDMO Market Share Forecast by Country (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Gene Cell Therapy CDMO Product Image Figure 3. Global Gene Cell Therapy CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 5. Global Gene Cell Therapy CDMO Market Share by Region: 2025 VS 2032 Figure 6. Global Gene Cell Therapy CDMO Market Share by Region (2021-2032) Figure 7. North America Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Immune Cells Image Figure 13. Global Immune Cells Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Stem Cell Image Figure 15. Global Stem Cell Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Viral Vector Image Figure 17. Global Viral Vector Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Plasmid DNA Image Figure 19. Global Plasmid DNA Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Gene Cell Therapy CDMO Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Gene Cell Therapy CDMO Market Share by Type 2025 VS 2032 Figure 22. North America Gene Cell Therapy CDMO Market Size Share by Type (2021-2032) Figure 23. Europe Gene Cell Therapy CDMO Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Gene Cell Therapy CDMO Market Size Share by Type (2021-2032) Figure 25. Latin America Gene Cell Therapy CDMO Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Gene Cell Therapy CDMO Market Size Share by Type (2021-2032) Figure 27. Pharmaceutical and Biotechnology Companies Image Figure 28. Global Pharmaceutical and Biotechnology Companies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Research and Academic Institutions Image Figure 30. Global Research and Academic Institutions Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Hospital Image Figure 32. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Others Image Figure 34. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Global Gene Cell Therapy CDMO Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Gene Cell Therapy CDMO Market Share by Application 2025 VS 2032 Figure 37. North America Gene Cell Therapy CDMO Market Size Share by Application (2021-2032) Figure 38. Europe Gene Cell Therapy CDMO Market Size Share by Application (2021-2032) Figure 39. Asia-Pacific Gene Cell Therapy CDMO Market Size Share by Application (2021-2032) Figure 40. Latin America Gene Cell Therapy CDMO Market Size Share by Application (2021-2032) Figure 41. Middle East and Africa Gene Cell Therapy CDMO Market Size Share by Application (2021-2032) Figure 42. Global Top 5 and 10 Gene Cell Therapy CDMO Players Market Share by Revenue in 2025 Figure 43. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 44. North America Gene Cell Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. North America Gene Cell Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. North America Gene Cell Therapy CDMO Market Share by Country (2021-2032) Figure 47. Europe Gene Cell Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Gene Cell Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Gene Cell Therapy CDMO Market Share by Country (2021-2032) Figure 50. Asia-Pacific Gene Cell Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Asia-Pacific Gene Cell Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Asia-Pacific Gene Cell Therapy CDMO Market Share by Country (2021-2032) Figure 53. Latin America Gene Cell Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Gene Cell Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Gene Cell Therapy CDMO Market Share by Country (2021-2032) Figure 56. Middle East & Africa Gene Cell Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Middle East & Africa Gene Cell Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Middle East & Africa Gene Cell Therapy CDMO Market Share by Country (2021-2032) Figure 59. Years Considered Figure 60. Research Process Figure 61. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Cells
  • Stem Cell
  • Viral Vector
  • Plasmid DNA
Applications
  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutions
  • Hospital
  • Others
Companies covered
  • Catalent
  • Lonza
  • Charles River
  • Oxford Biomedica
  • Novartis
  • OBiO
  • GenScript
  • Pharmaron
  • Porton
  • Resilience
  • SK Pharmteco
  • Forge Biologics
  • Andelyn Biosciences
  • Roslin CT
  • eXmoor Pharma
  • Advanced Therapies
  • Catalent Biologics
  • Patheon Pharma Services

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Gene Cell Therapy CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Gene Cell Therapy CDMO Market Size by Region (2021-2032)
  5. 1.4.1 Global Gene Cell Therapy CDMO Market Size by Region (2021-2026)
  6. 1.4.2 Global Gene Cell Therapy CDMO Market Size by Region (2027-2032)
  7. 1.5 Key Regions Gene Cell Therapy CDMO Market Size (2021-2032)
  8. 1.5.1 North America Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Gene Cell Therapy CDMO Market Size Growth Rate (2021-2032)
2 Gene Cell Therapy CDMO Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Immune Cells
  3. 2.1.2 Stem Cell
  4. 2.1.3 Viral Vector
  5. 2.1.4 Plasmid DNA
  6. 2.2 Global Gene Cell Therapy CDMO Market Size by Type
  7. 2.2.1 Global Gene Cell Therapy CDMO Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Gene Cell Therapy CDMO Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Gene Cell Therapy CDMO Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Gene Cell Therapy CDMO Market Size by Regions
  11. 2.3.1 North America Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Gene Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
3 Gene Cell Therapy CDMO Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Pharmaceutical and Biotechnology Companies
  3. 3.1.2 Research and Academic Institutions
  4. 3.1.3 Hospital
  5. 3.1.4 Others
  6. 3.2 Global Gene Cell Therapy CDMO Market Size by Application
  7. 3.2.1 Global Gene Cell Therapy CDMO Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Gene Cell Therapy CDMO Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Gene Cell Therapy CDMO Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Gene Cell Therapy CDMO Market Size by Regions
  11. 3.3.1 North America Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Gene Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Gene Cell Therapy CDMO Industry Trends
  2. 4.2 Gene Cell Therapy CDMO Industry Drivers
  3. 4.3 Gene Cell Therapy CDMO Industry Opportunities and Challenges
  4. 4.4 Gene Cell Therapy CDMO Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Gene Cell Therapy CDMO Revenue (2021-2026)
  2. 5.2 Global Gene Cell Therapy CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Gene Cell Therapy CDMO Key Company Headquarters & Area Served
  4. 5.4 Global Gene Cell Therapy CDMO Company, Product Type & Application
  5. 5.5 Global Gene Cell Therapy CDMO Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Gene Cell Therapy CDMO Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Gene Cell Therapy CDMO Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Gene Cell Therapy CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Catalent
  2. 6.1.1 Catalent Company Information
  3. 6.1.2 Catalent Business Overview
  4. 6.1.3 Catalent Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Catalent Gene Cell Therapy CDMO Product Portfolio
  6. 6.1.5 Catalent Recent Developments
  7. 6.2 Lonza
  8. 6.2.1 Lonza Company Information
  9. 6.2.2 Lonza Business Overview
  10. 6.2.3 Lonza Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Lonza Gene Cell Therapy CDMO Product Portfolio
  12. 6.2.5 Lonza Recent Developments
  13. 6.3 Charles River
  14. 6.3.1 Charles River Company Information
  15. 6.3.2 Charles River Business Overview
  16. 6.3.3 Charles River Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Charles River Gene Cell Therapy CDMO Product Portfolio
  18. 6.3.5 Charles River Recent Developments
  19. 6.4 Oxford Biomedica
  20. 6.4.1 Oxford Biomedica Company Information
  21. 6.4.2 Oxford Biomedica Business Overview
  22. 6.4.3 Oxford Biomedica Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Oxford Biomedica Gene Cell Therapy CDMO Product Portfolio
  24. 6.4.5 Oxford Biomedica Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Novartis Gene Cell Therapy CDMO Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 OBiO
  32. 6.6.1 OBiO Company Information
  33. 6.6.2 OBiO Business Overview
  34. 6.6.3 OBiO Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 OBiO Gene Cell Therapy CDMO Product Portfolio
  36. 6.6.5 OBiO Recent Developments
  37. 6.7 GenScript
  38. 6.7.1 GenScript Company Information
  39. 6.7.2 GenScript Business Overview
  40. 6.7.3 GenScript Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 GenScript Gene Cell Therapy CDMO Product Portfolio
  42. 6.7.5 GenScript Recent Developments
  43. 6.8 Pharmaron
  44. 6.8.1 Pharmaron Company Information
  45. 6.8.2 Pharmaron Business Overview
  46. 6.8.3 Pharmaron Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Pharmaron Gene Cell Therapy CDMO Product Portfolio
  48. 6.8.5 Pharmaron Recent Developments
  49. 6.9 Porton
  50. 6.9.1 Porton Company Information
  51. 6.9.2 Porton Business Overview
  52. 6.9.3 Porton Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Porton Gene Cell Therapy CDMO Product Portfolio
  54. 6.9.5 Porton Recent Developments
  55. 6.10 Resilience
  56. 6.10.1 Resilience Company Information
  57. 6.10.2 Resilience Business Overview
  58. 6.10.3 Resilience Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Resilience Gene Cell Therapy CDMO Product Portfolio
  60. 6.10.5 Resilience Recent Developments
  61. 6.11 SK Pharmteco
  62. 6.11.1 SK Pharmteco Company Information
  63. 6.11.2 SK Pharmteco Business Overview
  64. 6.11.3 SK Pharmteco Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 SK Pharmteco Gene Cell Therapy CDMO Product Portfolio
  66. 6.11.5 SK Pharmteco Recent Developments
  67. 6.12 Forge Biologics
  68. 6.12.1 Forge Biologics Company Information
  69. 6.12.2 Forge Biologics Business Overview
  70. 6.12.3 Forge Biologics Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Forge Biologics Gene Cell Therapy CDMO Product Portfolio
  72. 6.12.5 Forge Biologics Recent Developments
  73. 6.13 Andelyn Biosciences
  74. 6.13.1 Andelyn Biosciences Company Information
  75. 6.13.2 Andelyn Biosciences Business Overview
  76. 6.13.3 Andelyn Biosciences Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Andelyn Biosciences Gene Cell Therapy CDMO Product Portfolio
  78. 6.13.5 Andelyn Biosciences Recent Developments
  79. 6.14 Roslin CT
  80. 6.14.1 Roslin CT Company Information
  81. 6.14.2 Roslin CT Business Overview
  82. 6.14.3 Roslin CT Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Roslin CT Gene Cell Therapy CDMO Product Portfolio
  84. 6.14.5 Roslin CT Recent Developments
  85. 6.15 eXmoor Pharma
  86. 6.15.1 eXmoor Pharma Company Information
  87. 6.15.2 eXmoor Pharma Business Overview
  88. 6.15.3 eXmoor Pharma Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 eXmoor Pharma Gene Cell Therapy CDMO Product Portfolio
  90. 6.15.5 eXmoor Pharma Recent Developments
  91. 6.16 Advanced Therapies
  92. 6.16.1 Advanced Therapies Company Information
  93. 6.16.2 Advanced Therapies Business Overview
  94. 6.16.3 Advanced Therapies Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Advanced Therapies Gene Cell Therapy CDMO Product Portfolio
  96. 6.16.5 Advanced Therapies Recent Developments
  97. 6.17 Catalent Biologics
  98. 6.17.1 Catalent Biologics Company Information
  99. 6.17.2 Catalent Biologics Business Overview
  100. 6.17.3 Catalent Biologics Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Catalent Biologics Gene Cell Therapy CDMO Product Portfolio
  102. 6.17.5 Catalent Biologics Recent Developments
  103. 6.18 Patheon Pharma Services
  104. 6.18.1 Patheon Pharma Services Company Information
  105. 6.18.2 Patheon Pharma Services Business Overview
  106. 6.18.3 Patheon Pharma Services Gene Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Patheon Pharma Services Gene Cell Therapy CDMO Product Portfolio
  108. 6.18.5 Patheon Pharma Services Recent Developments
7 North America
  1. 7.1 North America Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Gene Cell Therapy CDMO Market Size by Country (2021-2026)
  3. 7.3 North America Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Gene Cell Therapy CDMO Market Size by Country (2021-2026)
  3. 8.3 Europe Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Gene Cell Therapy CDMO Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Gene Cell Therapy CDMO Market Size by Country (2021-2026)
  3. 10.3 South America Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Gene Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst